Carcinosarcoma clinical trials
The registry lists 74 studies for Carcinosarcoma across more than 10 countries. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-09.
Status
- Completed
- 33
- Terminated
- 12
- Active, not recruiting
- 10
- Recruiting
- 8
- Status unknown
- 6
- Withdrawn
- 3
Phase
- Phase 2
- 41
- Phase 1
- 16
- Phase 3
- 6
- Early Phase 1
- 1
Where
- United States
- 53
- Canada
- 11
- United Kingdom
- 6
- Germany
- 4
- Japan
- 2
- Puerto Rico
- 2
Who runs them
National Cancer Institute (NCI) (21) · Gynecologic Oncology Group (7) · Mayo Clinic (3) · University of Oklahoma (2) · M.D. Anderson Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Leap Therapeutics, Inc. (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 74 — search for more.
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingNCT05269381Phase 1/21 country
- Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial CancerRecruitingNCT05646316Phase 32 countries
- Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C TrialNot yet recruitingNCT07723235Not applicable1 country
- Agnostic Therapy in Rare Solid TumorsRecruitingNCT06638931Phase 21 country
- Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote MonitoringRecruitingNCT05500391Phase 21 country
- Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic PlatformRecruitingNCT063496421 country
- GISAR German Interdisciplinary Sarcoma RegistryRecruitingNCT041228721 country
- ONC201 and Atezolizumab in Obesity-Driven Endometrial CancerRecruitingNCT05542407Phase 11 country
- Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous CarcinomaRecruitingNCT055378441 country
- Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial CancerActive, not recruitingNCT03367741Phase 22 countries
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 11 country
- Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 22 countries
- Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerActive, not recruitingNCT03914612Phase 35 countries
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial CancerActive, not recruitingNCT04214067Phase 32 countries
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 22 countries
- A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsTerminatedNCT05949632Phase 1/21 country
- Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersActive, not recruitingNCT05691504Phase 11 country
- ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingNCT04065269Phase 22 countries
- (VELA) Study of BLU-222 in Advanced Solid TumorsTerminatedNCT05252416Phase 13 countries
- Expanded Access Use of DKN-01 for the Treatment of Advanced Solid TumorsNo longer availableNCT046812481 country
- A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or CarcinosarcomaCompletedNCT03395080Phase 21 country
- Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.CompletedNCT04458597Not applicable1 country
- Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
- ZW25 in Women With Endometrial CancersCompletedNCT04513665Phase 21 country
- Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast CancerCompletedNCT02983279Not applicable1 country
- Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal AdenocarcinomaTerminatedNCT03610490Phase 21 country
- Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 21 country
- Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT03552471Phase 11 country
- Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial CancerTerminatedNCT04906382Early Phase 11 country
- Pazopanib Vs. Pazopanib Plus GemcitabineActive, not recruitingNCT02203760Phase 21 country
- Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)CompletedNCT03648489Phase 22 countries
- A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)TerminatedNCT05001282Phase 1/21 country
- Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or OvaryCompletedNCT03206177Phase 11 country
- Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersCompletedNCT02020707Phase 11 country
- A Study of Durvalumab With or Without Tremelimumab in Endometrial CancerCompletedNCT03015129Phase 21 country
- The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer SurvivorsTerminatedNCT03641287Not applicable1 country
- Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine CancerTerminatedNCT01367301Not applicable1 country
- Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin DamageTerminatedNCT046887491 country
- Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersTerminatedNCT03924245Phase 11 country
- Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or CarcinosarcomaStatus unknownNCT05265793Phase 21 country
- Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?Status unknownNCT03570437Phase 21 country
- Nivolumab for Recurrent/Metastatic CarcinosarcomaStatus unknownNCT05224999Phase 21 country
- Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00989651Phase 11 country
- Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity CancerStatus unknownNCT00954174Phase 32 countries
- Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)CompletedNCT02993705Phase 21 country
- Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or ChemotherapyWithdrawnNCT03933761Phase 2
- Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological CancerWithdrawnNCT03902379Not applicable1 country
- Vorinostat (SAHA) in Uterine SarcomaTerminatedNCT03509207Phase 21 country
- Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial CancerCompletedNCT00478426Phase 22 countries
- Suitability of DCE-MRI for Detection of Vascular Changes After VBTCompletedNCT01991808Not applicable1 country